Head-to-head · free
AbCellera Biologics Inc. vs Becton, Dickinson and Company
ABCL vs BDX — return on capital, cash generation, margins and balance sheet side by side.
ABCL
1 / 6
measures where ABCL leads
BDX
5 / 6
measures where BDX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ABCL · FY2025 | BDX · FY2025 |
|---|---|---|
| Revenue | $75.1M | $21.8B |
| Net income | (146.4M) | $1.7B |
| Revenue growth (yearly, multi-year) | -33.1% | 1.9% |
| Free cash flow | (174.1M) | — |
| Free cash flow margin | -231.7% | — |
| Net cash / (debt) | — | — |
| ROIC | — | 5.1% |
| Return on equity | -14.5% | 6.5% |
| Gross margin | — | 45.4% |
| Operating margin | -270.5% | 13.7% |
| Net debt / EBITDA | 0.68x | 3.68x |
Figures are as reported by each company; latest fiscal year shown.
Where AbCellera Biologics Inc.'s cash went (FY2025)
- Capital spending
- $42.8M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Becton, Dickinson and Company's cash went (FY2025)
- Capital spending
- $760.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free